Skip to content
Roboearth – Lifestyle
Author:
Enterome
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
June 15, 2026
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
May 28, 2026
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
May 12, 2026